We have previously identified a novel complex between the platelet-derived growth factor (PDGF)β receptor and the sphingosine 1-phosphate receptor-1 (S1P 1 ). The complex permits the utilization of active G-protein subunits (made available by constitutively active S1P 1 receptor) by the PDGFβ receptor kinase to transmit signals to p42/p44 MAPK in response to PDGF. Therefore, an inverse agonist of the S1P 1 receptor is predicted to reduce signal transduction from PDGFβ receptor tyrosine kinase by blocking the constitutive activity of the G-protein coupled receptor. SB649146 is a novel inverse agonist of the S1P 1 receptor. First, SB649146 displaced the S1P 1 receptor agonist dihydrosphingosine 1-phosphate from membranes expressing the recombinant S1P 1 receptor. Second, SB649146 reduced basal recombinant S1P 1 receptorinduced GTPγS binding and S1P-induced GTPγS binding in membranes. Third, SB649146 blocked the S1P-induced activation of p42/p44 MAPK in airway smooth muscle cells, a response that is mediated by the S1P 1 receptor. We now report that inverse agonism of the S1P 1 receptor with SB649146 reduced the endocytosis of the PDGFβ receptor-S1P 1 receptor complex and the stimulation of p42/p44 MAPK and cell migration in response to PDGF. These findings are the first to report that a GPCR inverse-agonist reduces growth factor-induced receptor tyrosine kinase signaling, fundamentally broadening their mechanism of action. The data obtained with SB649146 also suggest that the constitutively active endogenous S1P 1 receptor enhances PDGFinduced cell migration.
Immunofluorescence
Cells were grown on 12 mm glass coverslips to 60-90% confluence and transfected as described. After treatment with PDGF for the times indicated, cells were fixed in 3.7% formaldehyde in PBS for 10 min then permeabilized in 0.1% Triton X100 in phosphate buffered saline for 1 min. Nonspecific binding was reduced by preincubating cells in blocking solution containing 5% FCS, 1% BSA in phosphate buffered saline for 1 h. Cells were incubated in primary antibodies (1:100 dilution in blocking solution) for 1 h at room temperature (or overnight at 4°C) and then incubated with the appropriate FITC or TRITC conjugated secondary antibodies (1:100) for 1 h. Detection of phosphorylated p42/p44 MAPK was enhanced by using a biotin conjugated secondary antibody (rabbit) followed by FITC conjugated streptavadin. Cells were mounted on glass slides using Vectashield mounting medium and visualized using a Nikon E600 epifluorescence microscopy.
GTP-γ-S binding assay
[ 35 S]GTPγS (1000 Ci/mmol) was obtained from Amersham Pharmacia Biotech (Piscataway, NJ). Briefly, cells were transiently transfected with 2 µg of S1P receptor plasmid construct. Twentyfour hours after transfection, membrane protein was collected by centrifugation at 100,000 g for 1 h at 4°C and suspended in 50 mM HEPES (pH 7.5), 100 mM NaCl, 1 mM MgCl 2 , and 2 mM EDTA. Ten micrograms of freshly prepared membrane protein were used for the assay. Membrane-bound radioactivity was separated by filtration using a Brandel Cell Harvester (Gaithersburg, MD) through a Whatman GF/B filter and quantitated by liquid scintillation counting. Samples were run at least in triplicates, and their mean ± SD was plotted as a function of S1P or SB649146 concentration.
[ 3 H]dihydro-S1P displacement
Lysis of S1P 1 receptor expressing HEK cells was performed for 40 min at 4°C in 50 mM HEPES-KOH, pH 7.6, 1 mM Na 2 EDTA, 100 µM leupeptin, and 5 µg/ml bacitracin. Nuclei were removed by centrifugation at 1000 g at 4°C for 20 min. Membranes were prepared by centrifugation at 48,000 g at 4°C for 30 min. The membranes were then homogenized and resuspended in 20 mM Tris pH 7.6, 15 mM NaF, 2 mM 4-deoxypyrydoxine, leupeptin (1 mg/ml), aprotinin (1.9 mg/ml), and PMSF (4 mg/ml). Membranes were combined with binding buffer (final concentration in well) composed of 20 mM Tris-HCl, pH 7.4, 15 mM NaF, 2 mM 4-deoxypyridoxine, BSA fatty acid free (Sigma A-8806), PMSF (4 mg/ml), aprotinin (1.9 mg/ml), and leupeptin (1 mg/ml). Five micrograms membrane protein and 0.5 nM dihydro-[ 3 H]S1P prepared by Biotrend were added to each well. Nonspecific binding was determined using a 100-fold excess of unlabeled dihydro S1P. After 30 min of incubation at room temperature under stirring, the microplate (pretreated with BSA 4 mg/ml in distilled H 2 O for 2 h) was filtered under vacuum and washed four times with 250 µl of binding buffer containing fatty-free acid BSA 0.4 mg/ml. Microplates were counted in a Wallac microbeta-scintillation counter 14 h after addition of 25 µl of scintillation fluid (Wallac, Optiphase). The IC 50 value was determined by fitting the data of three independent experiments to a sigmoidal curve using the program Grafit 3.0 (Ericthacus Software).
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Cell migration ASM cells were grown to 90-95% confluence and were quiesced by serum starvation. Tyrphostin AG1296, PD098059, or SB649146 was incubated with the cells for 30-60 min. The cell monolayer was wounded by a scratch using a 1 ml pipette tip. The wounded monolayer was then treated with PDGF (10 ng/ml) for 16 h. The area of cell-free wound was digitally photographed at 16 h. Images were analyzed by Image J software. The wound healing effect is presented as the percentage of closure of the wounded area. To visualize cells in the scratch assay, the cells were stained with Texas red phalloidin for actin and the fluorescence images were inverted. ASM cells were also cultured in 8-well ECIS electrode arrays (8W1E, Applied BioPhysics). Elevated field (3 V at 40,000 Hz for 10 s) was applied to obtain the wound of cell monolayer as described by Keese et al. (21) . Wound healing was monitored by measuring the increase of transcellular electrical resistance using ECIS machine (Applied BioPhysics).
RESULTS

Constitutively activated S1P 1 receptor enhances the PDGF-induced activation of p42/p44 MAPK
The hypothesis leading up to the first experiment in the present study is based on several previously reported observations concerning the interaction between S1P 1 and the PDGFβ receptor. We have shown that the PDGFβ receptor forms a complex with the S1P 1 receptor, which is functionally active in HEK 293 cells (5) . This was based on data showing that the complex can be co-immunoprecipitated from cell lysates using anti-PDGFβ receptor or anti-S1P 1 receptor antibodies (5, 6) . We have used HEK 293 cells because they are PDGFβ receptor null and express endogenous S1P 1 receptor. This represents a useful reconstitution expression system for evaluating the interaction between the ectopically expressed recombinant PDGFβ receptor and the endogenous S1P 1 receptor (5). We have also used ASM cells, as these express the endogenous PDGFβ receptor and S1P 1 receptor, which also form a functional signaling complex (6, 22) . The mechanisms regulating signal transmission from the PDGFβ receptor-S1P 1 receptor complex are highly similar in both HEK 293 and ASM cell systems (5, 6, 22) .
Several lines of evidence support a model in which the constitutively active S1P 1 receptor can enhance signal transmission from the PDGFβ receptor to p42/p44 MAPK. High level constitutive activity of the S1P 1 receptor has been described previously in several reports (14, 23) . In this respect, overexpressed wild-type S1P 1 receptor potentiated the PDGF-induced activation of p42/p44 MAPK in HEK 293 cells in the absence of exogenous S1P (5; Fig. 1A) . However, the use of the wild-type S1P 1 receptor in this case does not exclude the possibility that endogenous S1P might be released from HEK 293 cells in response to PDGF. This released S1P might potentially act on the S1P 1 receptor to induce activation of p42/p44 MAPK in response to PDGF. To evaluate this possibility, we used mutant S1P 1 receptors in which the binding of S1P is completely abolished. These mutants can also be used to evaluate constitutive receptor activity in the absence of S1P binding. In this regard, the R120A and E121A S1P 1 receptor mutants are completely defective in S1P binding (24) yet are able to potentiate the PDGF-stimulated activation of p42/p44 MAPK (Fig. 1B) . In the absence of PDGF, the constitutively active S1P 1 receptor does not induce stimulation of p42/p44 MAPK (Fig. 1C) . This has allowed us to test the hypothesis that inverse agonists that reduce the amount of constitutively active S1P 1 receptors should theoretically block the stimulation of p42/p44 MAPK by PDGF.
SB649146
, an inverse agonist of the S1P 1 receptor, blocks PDGF-induced signaling SB649146 is a novel inverse agonist of the S1P 1 receptor that stabilizes the inactive conformation of this receptor. This is based on several lines of evidence. First, SB649146 displaced the S1P 1 receptor agonist dihydrosphingosine 1-phosphate (IC 50 =300 nM) in HEK 293 cell membranes expressing recombinant S1P 1 receptor (Fig. 2A) . Second, SB649146 reduced basal constitutive S1P 1 receptor-induced GTPγS binding by ~70-75% ( Fig. 2B ; K i =10 nM) and antagonized S1P-induced GTPγS binding (Fig. 2C ) in HEK 293 cell membranes. Third, SB649146 reduced the S1P-induced activation of p42/p44 MAPK (Fig. 2D) . The role of the S1P 1 receptor was confirmed previously by results showing that anti-sense mediated down-regulation of this GPCR also abolished the S1P-induced activation of p42/p44 MAPK in these cells (6) . Further support for a role of the S1P 1 receptor was evident from the finding that the selective S1P 1 receptor agonist SEW2871 induced an activation of p42/p44 MAPK that was reduced by pretreating cells with SB649146 (Fig. 2D ).
The addition of SB649146 alone to ASM cells or HEK 293 cells (e.g., in the absence of PDGF or S1P) induced a small stimulation of the basal p42/p44 MAPK (Figs. 2D and E and 3A and B), suggesting that SB649146 can also stabilize, albeit weakly, the active conformation of the S1P 1 receptor. The SB649146-induced activation of p42/p44 MAPK represents <10% of the stimulation of p42/p44 MAPK with PDGF alone (Figs. 2D and E and 3A and B). The partial agonist effect of SB649146 was evident at concentrations >500 nM (data not shown) but was not detected in the GTPγS binding assay, suggesting that this effect may be masked by a predominant inverse agonism in this assay. The partial agonist effect of SB649146 on p42/p44 MAPK was blocked by pretreating ASM cells with PTX (Fig. 2D ).
The stabilization of the inactive S1P 1 receptor conformation by the inverse agonist SB649146 will reduce the amount of G i that can be activated and made available for use by the PDGFβ receptor kinase. This is based on a model in which the amount of the active conformation of the S1P 1 receptor will be reduced by the stabilization of the inactive conformation of this receptor by SB649146 via mass action. To investigate this possibility, we examined the effect of SB649146 on the PDGF-induced activation of p42/p44 MAPK in ASM cells. Data presented in Fig. 2D demonstrate that the treatment of ASM cells with SB649146 reduced the PDGF-induced stimulation of p42/p44 MAPK. These findings are corroborated by evidence showing that antisense-mediated down-regulation of the S1P 1 receptor also substantially reduced the PDGFinduced activation of p42/p44 MAPK in these cells (6) . We also assessed the effect of SB649146 on PDGFβ receptor signal transmission in HEK 293 cells. SB649146 abolished the PDGFinduced activation of p42/p44 MAPK in these cells (Fig. 2E ).
Immunofluorescent staining of ASM cells and Western blot analysis of subcellular fractions with an anti-phospho-p42/p44 MAPK antibody show that SB649146 reduced the PDGF-induced phosphorylation of p42/p44 MAPK in both the cytoplasm and nucleus ( Fig. 3A and B) . The data obtained with SB649146 are also supported by results showing that an alternative approach using PTX pretreatment also reduced the PDGF-induced phosphorylation of p42/p44 MAPK in both the cytoplasm and nucleus of ASM cells ( Fig. 3A and C) . PTX functions to uncouple G-protein coupled receptors from G i , thereby inhibiting S1P 1 receptor input that normally enhances PDGFβ receptor signal transmission (4-6, 22, 25) . Indeed, we have previously shown that the overexpression of the C-terminal tail of GRK2 (CT-GRK2), which sequesters Gβγ subunits, reduced the activation of p42/p44 MAPK by PDGF or S1P (22) . S1P-induced activation of p42/p44 MAPK was also abolished by PTX in these cells (26) .
Specificity of SB649146 action
SB649146 was without effect on basal GTPγS binding in HEK 293 cell membranes expressing recombinant S1P 2 or S1P 3 receptors, suggesting that SB649146 has no inverse or partial agonist activity against these receptors and exhibits exquisite specificity for the S1P 1 receptor (Fig. 4A) . Moreover, SB649146 was without effect on basal GTPγS binding in membranes expressing recombinant LPA 1 receptor, suggesting that SB649146 does not directly inhibit G i , which is coupled to the LPA 1 receptor (Fig. 4A) . SB649146 was without effect on the EGF-or PMAinduced activation of p42/p44 MAPK in ASM cells (Fig. 4B ). EGF-induced activation of p42/p44 MAPK is PTX insensitive, while anti-sense mediated down-regulation of the S1P 1 receptor has no effect on the stimulation of p42/p44 MAPK by PMA (5, 6) . Therefore, we can conclude that SB649146 has no effect on upstream regulators in the p42/p44 MAPK cascade (e.g., Raf, MEK) or p42/p44 MAPK itself. We have excluded a possible direct effect of SB649146 on PDGFβ receptor signaling that is independent of the S1P 1 receptor. This is evident from data presented in Fig. 4C . We have previously shown that PDGF induces the tyrosine autophosphorylation of the PDGFβ receptor in ASM cells, which can be detected by Western blotting ASM cell lysates with HRP-linked anti-phosphotyrosine antibody (4) . The involvement of the S1P 1 receptor/G i in regulating PDGFβ receptor signal transmission occurs downstream of the PDGFβ receptor and PDGFβ receptor tyrosine autophosphorylation. We therefore reasoned that SB649146 should have no effect on PDGF-stimulated tyrosine autophosphorylation of the PDGFβ receptor, unless it was interacting directly with this receptor, rather than with the S1P 1 receptor. Data presented in Fig. 4C demonstrate that SB649146 had no effect on PDGF-induced tyrosine autophosphorylation of the PDGFβ receptor.
A possible action of SB649146 in reducing PDGFβ receptor and S1P 1 receptor signaling by directly inhibiting G i -protein function was further excluded by data showing that the activation of the p42/p44 MAPK pathway by LPA, which uses the G i coupled receptor to stimulate this kinase pathway in HEK 293 cells (26) and PC12 cells (27) , was unaffected by SB649146 (Fig.  4D ).
SB649146 reduces PDGFβ receptor-S1P 1 receptor endocytosis
The PDGF-induced endocytosis of the PDGFβ receptor-S1P 1 receptor complex is an important step in the regulation of p42/p44 MAPK (6, 22) . To evaluate the effect of inverse agonism of the S1P 1 receptor with SB649146 on the endocytosis of the PDGFβ receptor, we transfected ASM cells with plasmid construct encoding the myc-tagged S1P 1 receptor. The idea here was to sequester the endogenous PDGFβ receptor with the myc-tagged S1P 1 receptor in a complex, such that the S1P 1 receptor in the complex could be detected with anti-myc tag antibody, as described previously by us (6) . Endocytosis of the PDGFβ receptor-S1P 1 receptor complex was evident from data showing that the PDGFβ receptor is colocalized with the myc-tagged recombinant S1P 1 receptor (as evidenced by yellow immunofluorescence in (Fig. 5A , merged panels) in endocytic vesicles of PDGF-stimulated ASM cells. Pretreatment of ASM cells with SB649146 reduced PDGF-induced endocytosis of the PDGFβ receptor-S1P 1 receptor complex (Fig. 5A) , as indicated by a reduction in the number of endocytic vesicles that contain PDGFβ receptor-S1P 1 receptor complex and that are yellow fluorescent. We also assessed the effect of SB649146 on PDGF-induced endocytosis of the PDGFβ receptor in cells not ectopically expressing the myctagged S1P 1 receptor. Under these conditions, the endogenous PDGFβ receptor is in a complex with the endogenous S1P 1 receptor (6). SB649146 markedly reduced PDGF-induced internalization of the PDGFβ receptor in these cells (Fig. 5B) . SB649146 also reduced the S1P-induced endocytosis of the myc-tag S1P 1 receptor (Fig. 5C ), thereby validating its inverse agonistic action of S1P 1 receptors. Typically, SB649146 alone induced a small increase in the number of myc-tagged S1P 1 receptors containing endocytic vesicles ( Fig. 5A and C) . Interestingly, SB649146 alone induces internalization of a pool of S1P 1 receptors that are not in a complex with the PDGFβ receptor, as S1P 1 receptor containing vesicles were not immunostained with anti-PDGFβ receptor antibody (e.g., there was no green fluorescence in these vesicles from cells treated with SB649146 alone).
Effect of SB649146 on PDGF-stimulated cell migration
We hypothesized that the constitutive activity of the S1P 1 receptor might enhance PDGFstimulated cell migration. Evidence that supports this possibility was the demonstration that PTX abolished cell migration in response to PDGF (Fig. 6A) . Therefore, the ability of PDGF to induce cell migration appears to be dependent on G-protein/GPCR involvement. The pretreatment of ASM cells with tyrphostin AG 1296, a PDGF receptor tyrosine kinase inhibitor, or PD098059, an inhibitor of MEK-1 activation by Raf kinase, also reduced PDGF-stimulated cell migration ( Fig. 6B and C) . The findings suggest a key role for the PDGF receptor kinase-dependent stimulation of the p42/p44 MAPK pathway in regulating cell migration. Finally, a role for the PDGFβ receptor-S1P 1 receptor complex was demonstrated by evidence showing that pretreatment of ASM cells with SB649146 reduced PDGF-stimulated cell migration ( Fig. 7A and  B) . The S1P 1 receptor selective agonist SEW2871 or the S1P 1 receptor inverse agonist SB649146 alone was without effect on cell migration ( Fig. 7A and B; data not shown). S1P alone exhibited an inhibitory effect on basal cell migration (Fig. 8) . This may be due to the fact that in addition to stimulatory S1P 1 receptors, smooth muscle cells express S1P 2 receptors that inhibit cell migration (19) . Indeed, the inhibitory effect of S1P on cell migration is not reduced by pretreating ASM cells with PTX (Fig. 8) , suggesting that the inhibitory S1P receptor involved does not use G i to mediate its effect.
Regulation of myosin light chain (MLC20) phosphorylation
To further substantiate a link between the PDGFβ receptor-S1P 1 receptor complex, p42/p44 MAPK, and cell migration, we evaluated the effect of SB649146 on MLC20 phosphorylation. MLC20 is an established substrate of MLCK, which is phosphorylated by cytoplasmic p42/p44 MAPK and is involved in regulating cell migration (28) . Results presented in Fig. 9 demonstrate that PDGF induced the phosphorylation of MLC20 and that treatment of cells with SB649146 reduced this effect.
Page 8 of 25 (page number not for citation purposes)
DISCUSSION
The findings of this study are the first to report that a GPCR inverse agonist can be used to reduce growth factor-induced receptor tyrosine kinase signaling and regulation of cell migration. This not only invokes a major paradigm shift in our understanding of how growth factors function but also necessitates a complete re-evaluation of how inverse agonists of GPCR (which also act as competitive antagonists) function. This is of immediate interest, as over 70% of all known therapeutic drugs act as GPCR antagonists, suggesting that their therapeutic efficacy might be related to the action of RTK-GPCR complexes rather than simply on the GPCR alone.
The novel inverse agonist SB649146 blocks the constitutive activity of the S1P 1 receptor. Constitutive activation of the S1P 1 receptor occurs under conditions where a significant fraction of the receptor exists in the active conformation in the absence of S1P. The ability of the constitutively active S1P 1 receptor to enhance PDGFβ receptor signaling is based on three findings. First, the elimination of S1P 1 receptor expression using anti-sense substantially reduced the PDGF-induced activation of p42/p44 MAPK in ASM cells (6) . Second, SB649146 reduced the activation of p42/p44 MAPK by PDGF in cells expressing the S1P 1 receptor. Third, the overexpression of S1P 1 receptor mutants (R120A and E121A) that are completely defective in their ability to bind S1P was able to potentiate the PDGF-induced stimulation of p42/p44 MAPK. A model for the action of the constitutively active S1P 1 receptor is as follows. The S1P 1 receptor stimulates G i activation in the absence of S1P. G i α is then tyrosine phosphorylated by the PDGFβ receptor kinase in response to PDGF. The tyrosine-phosphorylated G i α and active Gβγ subunits made available by the constitutively active S1P 1 receptor enhance PDGF-induced stimulation of the p42/p44 MAPK pathway (5) . Therefore, by blocking the constitutive activity of the S1P 1 receptor, the inverse agonist SB649146 appears to reduce availability of the Gprotein subunits for use by the PDGFβ receptor.
Over-expression of the constitutively active S1P 1 receptor does not result in activation of p42/p44 MAPK but enhances PDGF-induced activation of this kinase pathway. We have previously shown that this occurs, as PDGF is required to recruit c-Src to the PDGFβ receptor-S1P 1 receptor complex (6, 22) . Once c-Src has been recruited, it can then initiate signal relay from the PDGFβ receptor-S1P 1 receptor complex to p42/p44 MAPK. Indeed, c-Src catalyzes the G i -dependent tyrosine phosphorylation of Gab1, required for endocytosis of the PDGFβ receptor-S1P 1 receptor complex, a step that leads to activation of p42/p44 MAPK in response to PDGF (22, 25) . This is therefore compatible with a model in which G i activation by the constitutively active S1P 1 receptor stimulates c-Src that has been recruited to the PDGFβ receptor-S1P 1 receptor complex in response to PDGF. Indeed, we have previously shown that PTX reduces the PDGF-induced stimulation of c-Src in ASM cells (4) . Taken together with the current study, the findings suggest an important role of the constitutively active S1P 1 receptor in regulating G i -dependent endocytosis of the PDGFβ receptor-S1P 1 receptor complex in response to PDGF. Indeed, we have previously shown that PDGF-induced endocytosis of the PDGFβ receptor-S1P 1 receptor complex is blocked by PTX and c-Src inhibitors (22) . This model is therefore entirely compatible with evidence presented here that shows that inverse agonism of the S1P 1 receptor with SB649146 reduces the PDGF-induced endocytosis of the PDGFβ receptor-S1P 1 receptor complex and thereby p42/p44 MAPK activation and cell migration.
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SB649146 also appears to be able to interact with different conformational states of the S1P 1 receptor. The partial agonism elicited by SB649146 alone occurs due to fractional activation of the active state of S1P 1 receptor, which is manifested as a small stimulation of p42/p44 MAPK. However, from the GTPγS assay, it is evident that a larger proportion of the S1P 1 receptor in the inactive conformation is stabilized by SB649146. Thus, SB649146 acts as an inverse agonist and reduces constitutive S1P 1 receptor-stimulated GTPγS binding. Thus, when S1P or PDGF is used to stimulate the p42/p44 MAPK, SB649146 has an inhibitory effect because its inverse agonism of the S1P 1 receptor vastly reduces the amount of the active conformation of the S1P 1 receptor that can be stabilized by S1P or that can be effectively engaged by the PDGFβ receptor. This occurs via a mass action effect due to predominant stabilization of the inactive conformation of the S1P 1 receptor by SB649146. This model is consistent with the well-established phenomenon whereby ligands can bind to both conformational states of the receptor determined by individual rate constants. In addition, the partial agonist effect of SB649146 seems to access a pool of S1P 1 receptors that are not in a complex with the PDGFβ receptor. Therefore, the S1P 1 receptor can exist in an active and inactive conformation in the complex with the PDGFβ receptor and in an active/inactive conformation when "free." Thus, stabilization of the active conformation by SB649146 appears specific for the free S1P 1 receptor. The free S1P 1 receptor:S1P 1 receptor-PDGFβ receptor complex ratio might be determined by the expression levels of the two receptors. In this regard, the ratio is ~1:10 in ASM cells (Fig. 5A , comparing red fluorescent S1P 1 containing endocytic vesicles in PDGF plus SB649146 treated cells with the colocalized S1P 1 receptor and PDGFβ receptor containing endocytic vesicles that are yellow fluorescent in response to PDGF). The effects of SB649146 in terms of inverse agonism vs. partial agonism are therefore likely to be cell type specific, and the utility of this reagent must consider this ratio. In this regard, SB649146 represents the first chemical agent that can be used to probe RTK-GPCR integrative signal complexes.
The antagonistic effect of SB649146 on the PDGFβ receptor signaling is not accounted for by competition with S1P that is potentially released in response to PDGF. This was based on previous results showing that inhibitors of the enzyme sphingosine kinase (e.g., D,L-threo dihydrosphingosine, N,N-dimethylsphingosine), responsible for synthesizing S1P, or the overexpression of wild-type or dominant negative sphingosine kinase 1, have no effect on the PDGF-induced activation of p42/p44 MAPK in ASM or HEK 293 cells (5, 6) .
A study describing a similar model on RTK-GPCR integrative signaling has been very recently described demonstrating that the chemokine GPCR CXCR4 and IGF-1R and G-protein subunits G i α2 and Gβ are constitutively associated in a complex in MDA-MB-321 cells (29) . This complex regulates migratory signaling in these cells. The authors propose that stimulation of cells with IGF-1 leads to the activation of G i associated with the CXCR4-IGF-1R complex, based on dissociation of G i α and β from the complex. Our current data are critical in resolving the general mechanism here. Thus, the ability of an inverse agonist of the S1P 1 receptor to block PDGFβ receptor signal transmission suggests that the supply of activated G-protein is dependent on the constitutive activity of the GPCR in the complex with the RTK and not on growth factor, as suggested by Akekawatchai and colleagues (29) . Therefore, G-protein subunits are preassociated with the RTK-GPCR complex and are activated by the constitutively active GPCR. It is entirely feasible then that the active G-protein subunits dissociate from the complex on ligation of the RTK with growth factor and that dissociation is dependent on the tyrosine phosphorylation of active G i α by the RTK in response to growth factor. Indeed, we have previously shown that PDGF induces tyrosine phosphorylation of G i α (5) and that this is a critical step for regulating downstream signal transmission from the PDGFβ receptor-S1P 1 receptor complex to c-Src, Gab1, and p42/p44 MAPK in response to PDGF (5, 22) . This explanation is entirely in line with the finding that PTX, which uncouples G i from GPCR, can reduce RTK signal transmission (4) (5) (6) 29) .
The use of the S1P 1 receptor inverse agonist SB649146 has also provided new information concerning the physiological role of the PDGFβ receptor-S1P 1 receptor complex in regulating cell migration. This is based on data showing that SB649146 reduced PDGF-stimulated cell migration. The regulation of cell migration by PDGF involves MLC20 phosphorylation. In this regard, we have demonstrated that SB649146 reduced PDGF-induced phosphorylation of MLC20. We therefore propose that MLCK integrates signals transmitted from the PDGFβ receptor-S1P 1 receptor complex to regulate cell migration. S1P itself has an inhibitory effect on migration that is possibly mediated by the S1P 2 receptor. Stimulation of the S1P 1 receptor with the selective S1P 1 receptor agonist SEW2871 did not induce cell migration. Therefore, the S1P 1 receptor appears to function only to amplify PDGF-stimulated cell migration. The reason why stimulation of the S1P 1 receptor with SEW2871 does not itself regulate cell migration is unknown. There are several possibilities. For instance, SEW2871 may not activate sufficient p42/p44 MAPK to breach a threshold required for regulation of cell migration. Alternatively, PDGF may activate additional migratory signals that are convergent with signals transmitted by the PDGFβ receptor-S1P 1 receptor complex to p42/p44 MAPK.
These data resolve significant issues within the field. Spiegel's group (30) has proposed that PDGF induces the release of S1P, which can act on either S1P 1 receptors to stimulate migration or S1P 2 to inhibit PDGF-induced cell migration. The biological action of S1P at S1P 1 and S1P 2 receptors occurs in the same cell type, although the precise mechanism defining which of these opposing actions is predominant remains unknown. Our findings are compatible with a model in which the basal constitutive activity of the S1P 1 receptor enhances PDGF-induced migration, while S1P acts via S1P 2 to inhibit migration.
In summary, the findings of this study are to our knowledge the first to report that an inverse GPCR agonist is able to disrupt RTK signaling, thereby fundamentally altering our concept of how these drugs act. We have also applied this new information concerning the mechanism of action of the inverse agonist to establish a major role for RTK-GPCR complexes in regulating a key physiological response, namely cell migration. MAPK. HEK 293 cells were transiently transfected with vector or plasmid constructs encoding WT S1P 1 , S1P 1 R120A, or S1P 1 E121A receptor mutants and/or PDGFβ receptor. Cells were then stimulated with and without PDGF (10 ng/ml) for 10 min. Western blots show the following: A) effect of WT S1P 1 overexpression on PDGF-stimulated activation of p42/p44 MAPK; B) effect of S1P 1 R120A and S1P 1 E121A receptor mutants on PDGF-stimulated activation of p42/p44 MAPK. Also shown are blots probed with anti-PDGFβ receptor or anti-S1P 1 receptor antibodies to confirm overexpression of each protein; C) lack of effect of S1P 1 R120A and S1P 1 E121A receptor mutants on basal p42/p44 MAPK activation state. Blots were probed with anti-p42 MAPK antibody to confirm equal protein loading. Fig. 4 (cont)   Figure 4 . Specificity of SB649146. A) HEK 293 cells were separately transfected with plasmid constructs encoding S1P 2 , S1P 3 , and LPA 1 receptors. Graphs show lack of effect of SB649146 on basal GTPγS binding in membranes from S1P 2 -, S1P 3 -, and LPA 1 -transfected HEK 293 cells. For S1P 2 and S1P 3 , S1P-stimulated GTPγS binding was also measured to ensure functional expression of these receptors, while LPA-stimulated GTPγS binding was measured for LPA 1 5 . Endocytosis of the PDGFβ receptor-S1P 1 receptor complex. ASM cells were transfected with plasmid construct encoding myc-tagged S1P 1 receptor. ASM cells were pretreated with and without SB649146 (10 μM) for 30 min before stimulation of cells with S1P (5 μM) or PDGF (10 ng/ml) for 5 min. Photographs show the following: A) SB649146 inhibits PDGF-induced cointernalization of the PDGFβ receptor (detected with anti-PDGFβ receptor antibody and FITC secondary antibody, green) and myc-tagged S1P 1 receptor (ectopic expression and detected with anti-myc tag antibody and TRITC secondary antibody, red). Merged images demonstrating colocalization of the PDGFβ receptor and myc-tagged S1P 1 receptor (yellow fluorescence) are also shown. Examples of endocytic vesicles containing myc-tagged S1P 1 receptor (red) or PDGFβ receptormyc-tagged S1P 1 receptor complexes (yellow) are marked with arrows; B) SB649146 inhibits the PDGFinduced internalization of the PDGFβ receptor (detected with anti-PDGFβ receptor antibody and FITC secondary antibody) in cells expressing endogenous S1P 1 receptor. Examples of endocytic vesicles containing PDGFβ receptor are marked with arrows; C) SB649146 reduced the S1P-induced endocytosis of the myctagged S1P 1 receptor (detected with anti-myc tag antibody and TRITC secondary antibody). Examples of endocytic vesicles containing myc-tagged S1P 1 receptor are marked with arrows. 
